FDA to review Xarelto safety concerns
March 19, 2009Research and Development, Sales and Marketing Xarelto
Anti-blood clotting drug Xarelto could fail to win approval in the US due to safety concerns. The FDA has convened …
ProStrakan ‘on target’ to break-even this year
March 19, 2009Sales and Marketing ProStrakan
ProStrakan says it will move into the black later this year, after sales rose by a third and its operating …
Biosimilars bill offers 12 years’ marketing exclusivity
March 19, 2009Research and Development US, generics
The US moved one step closer to creating a market for biosimilars – substitutable versions of branded biologic drugs – …
Hamburg appointed as new FDA head
March 18, 2009Research and Development FDA
A leading public health expert has been appointed as the new head of the FDA. President Obama has selected Dr …
Patent office shows tougher stance on “evergreening”
March 18, 2009Research and Development Europe
The rate of patent applications refused in Europe has risen to an all time high, as authorities target "evergreening" of …
Getting the most out of your product portfolio
March 17, 2009Research and Development, Sales and Marketing portfolio, product
Portfolio planning should be a practical process that delivers a programme of work to take you to sunnier shores. All …
One in five European biotech companies facing bankruptcy
March 17, 2009Research and Development biotech
Around one in five European biotech companies could go bust by the end of 2009 if new funding doesn't emerge …
Unlocking the value of social media for business customers
March 17, 2009Medical Communications, Sales and Marketing marketing, social networking
Conversations around social media dominate the marketing landscape. Twitter-mania has reached fever pitch, proclaiming it the latest 'must have' social …
The internet marketing code
March 17, 2009Medical Communications, Sales and Marketing code, marketing, new media, online
Merck’s mega-merger will mark a return to sales growth
March 16, 2009Sales and Marketing MA, Merck
As a standalone company, Merck & Co. faces a tough future of declining sales. Analysts Datamonitor forecast that the merger …
Mannkind picks up Pfizer’s Exubera facility
March 16, 2009Manufacturing and Production Mannkind, diabetes
The demise of Pfizer's inhaled diabetes treatment Exubera cast a pall over the prospects for inhaled insulin therapy, but has …
Blow for Genzyme as FDA finds fault with Allston facility
March 13, 2009Research and Development, Sales and Marketing FDA, Genzyme
The chances of approval for Genzyme's new Pompe disease drug Lumizyme have diminished dramatically after the US Food and Drug …
Working Life: Andrew Clark
March 13, 2009Research and Development, Sales and Marketing UCB, library
How did you find your way into your current role? On return from a working holiday to New Zealand I …
Government picks top-level NHS-academic research centres
March 12, 2009Research and Development Academic
Five establishments have been named by the government as Academic Health Science Centres (AHSCs). The centres – UCL Partners, Cambridge …
Roche buys out Genentech with increased bid
March 12, 2009Sales and Marketing MA, Roche
Roche has finally struck a deal to acquire Genentech after raising its cash offer, putting an end to a prolonged …
Cervarix adverse reactions as expected, says MHRA
March 11, 2009Sales and Marketing GSK, vaccines
The government has played down reports about adverse reactions to GlaxoSmithKline's Cervarix, saying they are in line with expectations. The …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
